-
Views
-
Cite
Cite
Karl Norris, Lisa Shaw, Jane Elizabeth Alder, Clare Louise Lawrence, P47
THE IDENTIFICATION OF NOVEL APTAMERS TO GLIOMA, Neuro-Oncology, Volume 16, Issue suppl_6, October 2014, Pages vi7–vi8, https://doi.org/10.1093/neuonc/nou249.35Close - Share Icon Share
Abstract
INTRODUCTION: Glioma represent less than 2% of all cancer cases in the UK, however, 80% of these tumours are glioblastoma (GBM). GBM is a highly aggressive tumour with poor patient survival rates, despite treatment involving surgery and radiotherapy with adjuvant chemotherapy. Delivery systems that have the ability to distinguish neoplasms from non-cancerous tissues, such as aptamers, may improve patient outcome. Aptamers have previously been shown to selectively target glioma cell lines. Aptamers can also be raised to known biomarkers that are crucial for cell survival, and once bound may inhibit glioma growth. The aim of this study was to produce novel aptamers to known glioma targets and to optimise the systematic evolution of ligands by exponential enrichment (SELEX) procedure with a view to produce Aptamers against patient tissue biopsies which ultimately have low cell numbers. METHOD: Cell lines SVGp12 and U87MG were utilised to determine the lowest number of cells which returned detectable DNA aptamers. Each iterative round of SELEX was optimised by determining the optimal number of touchdown PCR cycles. Furthermore, aptamers were selected against biomarkers related to gliomagenesis via counter SELEX. RESULTS: Optimisation of cell SELEX showed 100 cells and 15-17 cycles of TD-PCR were sufficient for selection. After 6 rounds of counter SELEX, aptamers selected towards a biomarker indicative of glioma were sequenced. CONCLUSION: Aptamers were selected using minimal amounts of sample, and the optimised procedure will now be used to identify aptamers which target primary tissues. Specificity of sequenced aptamers to the known biomarker and potential inhibition of glioma growth will be confirmed in future studies.
